Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy (maintenance of remission) and safety of etrolizumab compared with placebo in patients with moderate to severe active ulcerative colitis who are naive to TNF inhibitors

HS 2015-2537
Ulcerative colitis, Inflammatory Bowel Disease, Digestive Disease, Crohn’s disease
Nimisha K. Parekh, MD
UC Irvine Medical Center
To determine whether etrolizumab is a safe and effective treatment for ulcerative colitis in patients with moderately to severely active ulcerative colitis who have previously been treated with corticosteroids and/or immunosuppressants such as azathioprine, 6-mercaptopurine and methotrexate, and their condition did not improve.
Patients with moderately to severely active ulcerative colitis who have previously been treated with corticosteroids and/or immunosuppressants such as azathioprine, 6-mercaptopurine and methotrexate, and their condition did not improve.
18 visits of approximately 1.5 hours each for 62 weeks.
$25 per visit
etrolizumab
Drug therapy
III
Scott Graf, Clinical Research Coordinator, Gastroenterology
714-456-7033